The type of androgenetic alopecia and quality of life (QoL) in male patients

Khairina Nasution; Raynald Pradigo; Rudi Chandra

doi:10.19106/JMedSci005401202205

The type of androgenetic alopecia and quality of life (QoL) in male patients

https://doi.org/10.19106/JMedSci005401202205

Khairina Nasution⁽¹⁾, Raynald Pradigo⁽²⁾, Rudi Chandra^(3*)

(1) Department of Dermatology and Venerology, Faculty of Medicine, University of Sumatera Utara, Medan
(2) Faculty of Medicine, University of Sumatera Utara, Medan
(3) Department of Dermatology & Venereology, Faculty of Medicine, University of Prima Indonesia, Medan
(*) Corresponding Author

Abstract

Androgenetic alopecia (AGA) is a nonscarring baldness that mostly affects >50% men worldwide. Hair loss led to psychological difficulties and have a negative impact on the quality of life (QoL). This study aimed to evaluate the relationship between the type of AGA and QoL in male patients. A total of 67 male AGA patients were clinically assessed using the Hamilton-Norwood scale and interviewed using the Hair-Specific Skindex-29 scale to assess QoL. The patients were predominantly in the age group 31-50 years (50.7%), mean age 49.60 years, grade I obese (32.8%), mean BMI 24.93 kg/cm², 41.8% with father’s AGA history, smoking (62.7%), smoking >100 cigarettes in last 6 months (41.8%), and have hypertension (16.4%) and diabetes mellitus (3%) as concomitant diseases. Based on Noorwood-Hamilton scale, the types of AGA were predominantly type II (25.4%) and followed by type III (16.4%). The results of the Hair Specific Skindex-29 on AGA patients were moderate (58.2%) and severe (41.8%). There were a relationship between AGA type and QoL (p = 0.041) and significant positive correlation between AGA type and QoL (p = 0.020, r = 0.282). In conclusion, patients experienced moderate to severe impact on QoL due to AGA. Thus, every increased in the type of AGA will impact patient’s quality of life.

Keywords

androgenetic alopecia, hair-spesific Skindex-29, quality of life

Full Text:

PDF

References

1.Blume-Peytavi U & Kanti V. Androgenetic Alopecia. In: Kang S, Amagai , Bruckner AL, Enk AH, Margolis DJ, McMichael AJ, Orringer JS, editors. Fitzpatrick’s Dermatology. 9th ed. New York: McGraw-Hill Companies; 2019:p.1495-1506.
2.Ghimire RB. Impact on quality of life in patients who came with androgenetic alopecia for hair transplantion surgery in a clinic. J Nepal Med Assoc 2018; 56(212):763-5.
3.Sawant N, Chikhalkar S, Mehta V, Ravi M, Madke B, Khopkar U. Androgenetic alopecia: quality-of-life and associated lifestyle patterns. Int J Trichology 2010; 2(2):81-5.
https://doi.org/10.4103/0974-7753.77510
4.Hunt N, McHale S. The psychological impact of alopecia. BMJ 2005; 331(7522):951-3.
https://doi.org/10.1136/bmj.331.7522.951
5.Alfonso M, Richter-Appelt H, Tosti A, Viera MS, García M. The psychosocial impact of hair loss among men: A multinational European study. Curr Med Res Opin 2005; 21(11):1829-36.
https://doi.org/10.1185/030079905X61820
6.Williamson D, Gonzalez M, Finlay AY. The effect of hair loss on quality of life. J Eur Acad Dermatol Venereol 2001; 15(2):137-9.
https://doi.org/10.1046/j.1468-3083.2001.00229.x
7.Reid EE, Haley AC, Borovicka JH, Rademaker A, West DP, Colavincenzo M, et al. Clinical severity does not reliably predict quality of life in women with alopecia areata, telogen effluvium, or androgenic alopecia. J Am Acad Dermatol 2012; 66(3):e97-102.
https://doi.org/10.1016/j.jaad.2010.11.042
8.Gonul M, Cemil BC, Ayvaz HH, Cankurtaran E, Ergin C, Gurel MS. Comparison of quality of life in patients with androgenetic alopecia and alopecia areata. An Bras Dermatol 2018; 93(5):651-8.
https://doi.org/10.1590/abd1806-4841.20186131
9.Bade R, Bhosle D, Bhagat A, Shaikh H, Sayyed S, Shaikh A. Impact of androgenic alopecia on the quality of life in male subjects: results of an observational study from Tertiary Care Hospital. JMSCR 2016; 4(10):12900-07.
https://doi.org/10.18535/jmscr/v4i10.05
10.Chren MM, Lasek RJ, Flocke SA, Zyzanski SJ. Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases. Arch Dermatol 1997; 133(11):1433-40.
11.Han SH, Byun JW, Lee WS, Kang H, Kye YC, Kim KH, et al. Quality of life assessment in male patients with androgenetic alopecia: result of a prospective, multicenter study. Ann Dermatol 2012; 24(3):311-8.
https://doi.org/10.5021/ad.2012.24.3.311
12.Prinsen CA, Lindeboom R, Sprangers MA, egierse CM, de Korte J. Health-related quality of life assessment in dermatology: interpretation of Skindex-29 scores using patient-based anchors. J Invest Dermatol 2010; 130(5):1318-22.
https://doi.org/10.1038/jid.2009.404
13.Krupa Shankar DS, Chakravarthi M, Shilpakar R. Male androgenetic alopecia: population-based study in 1,005 subjects. Int J Trichology 2009; 1(2):131-3.
https://doi.org/10.4103/0974-7753.58556
14.Salman KE, Altunay IK, Kucukunal NA, Cerman AA. Frequency, severity and related factors of androgenetic alopecia in dermatology outpatient clinic: hospital-based cross-sectional study in Turkey. An Bras Dermatol 2017; 92(1):35-40.
https://doi.org/10.1590/abd1806-4841.20175241
15.Chumlea WC, Rhodes T, Girman CJ, Johnson-Levonas A, Lilly FRW, Wu R, et al. Family history and risk of hair loss. Dermatology 2004; 209(1):33-9.
https://doi.org/10.1159/000078584
16.Trüeb RM. Association between smoking and hair loss: Another opportunity for health education against smoking?. Dermatology 2003; 206(3):189-91.
https://doi.org/10.1159/000068894
17.Yang CC, Hsieh FN, Lin LY, Hsu CK, Sheu HM, Chen W. Higher body mass index is associated with greater severity of alopecia in men with male-pattern androgenetic alopecia in Taiwan: a cross-sectional study. J Am Acad Dermatol 2014; 70(2):297-302.e1.
https://doi.org/10.1016/j.jaad.2013.09.036
18.Kamycheva E, Berg V, Jorde R. Insulin-like growth factor I, growth hormone, and insulin sensitivity: the effects of a one-year cholecalciferol supplementation in middle-aged overweight and obese subjects. Endocrine 2013; 43(2):412-8.
https://doi.org/10.1007/s12020-012-9825-6
19.Su LH, Chen THH. Association of androgenetic alopecia with smoking and its prevalence among asian men: a community-based survey. Arch Dermatol 2007; 143(11):1401-6.
https://doi.org/10.1001/archderm.143.11.1401
20.Gok SO, Belli AA, Dervis E. Is there really relationship between androgenetic alopecia and metabolic syndrome?. Dermatol Res Pract 2015; 2015:980310.
https://doi.org/10.1155/2015/980310
21.Ellis JA, Stebbing M, Harrap SB. Male pattern baldness is not associated with established cardiovascular risk factors in the general population. Clin Sci (Lond) 2001; 100(4):401-4.
22.Ahouansou S, Le Toumelin P, Crickx B, Descamps V. Association of androgenetic alopecia and hypertension. Eur J Dermatol 2007; 17(3):220-2.
https://doi.org/10.1684/ejd.2007.0152
23.Sezgin SA, Altunay L, Köşlü A. Androgenetik alopeside koroner arter hastalığı risk faktörleri. Türkderm 2000; 34(2):95-9.
24.Mansouri P, Mortazavi M, Eslami M, Mazinani M. Androgenetic alopecia and coronary artery disease in women. Dermatol Online J 2005; 11(3):2.
25.Yi SM, Son SW, Lee KG, Kim SH, Lee SK, Cho ER, et al. Gender-spesific association of androgenetic alopecia with metabolic syndrome in a middle-aged Korean population. Br J Dermatol 2012; 167(2):306-13.
https://doi.org/10.1111/j.1365-2133.2012.10978.x
26.Jun M, Keum DI, Lee S, Kim BJ, Lee WS. Quality of life with alopecia areata versus androgenetic alopecia assessed using hair specific Skindex-29. Ann Dermatol 2018; 30(3):388-91.
https://doi.org/10.5021/ad.2018.30.3.388

DOI: https://doi.org/10.19106/JMedSci005401202205

Article Metrics

Abstract views : 973 |

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

View My Stats

Journal of the Medical Sciences (Berkala Ilmu Kedokteran) by Universitas Gadjah Mada is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Based on a work at http://jurnal.ugm.ac.id/bik/.

Username
Password
Remember me